Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME
The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.
A dive into financial relationships between industry and doctors showed women receive less money for research, education and speaking than men.
The Centers for Medicare and Medicaid Services last year published 4.45 million records about financial relationships between industry and HCPs.
The CMS said the issues should be resolved this week and will not affect this month's deadline for companies to submit payment data from 2014.
A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.
Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
The drugmaker revealed part 2 of its plan not to pay doctors to speak on GSK's behalf: it will make them employees.
A report indicates pharma companies do not agree on what research needs to be reported.
Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.
A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
Business briefs: Reps mum on adverse events; FCC's new mHealth director; med schools tighten speaking limitsApril 11, 2013
A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation
BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales
Gift bans or no, students still connect with drug companies, a study has found.
New transparency rules set to lay bare financial ties between physicians and pharma will be a mixed bag for medical education, providers say.
Clinical Research Organizations, marketing research firms, accredited CME providers and lawyers look to be the big winners in CMS's Sunshine Act rule.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.
CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
Abbott releases its 2012 numbers, Sen. Grassley demands Sunshine Act action from CMS and Allergan and Watson flex their purchasing power.
Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.
GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.
As the Massachusetts Department of Public Health deliberates the exact shape of a rule change allowing industry-sponsored meals for physicians in speaker programs, pharma foes and industry advocates are squaring off over the definition of "modest meals and refreshments."
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.